#Diabetes #Obesity #GLP1 #HealthcareInnovation #Pharmaceuticals #CardiometabolicHealth To view or add a comment, sign in More Relevant Posts Eli Lilly and Company reported results from ACHIEVE-3, the first head-to-head #Phase3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with #Type2Diabetes
Its helpful to track how you feel in the days following your first shot
Male and female age 18 years old and above
Liraglutide is indicated as an adjunct to a reduced-energy diet and increased physical activity for weight loss management in adults with a BMI 30 kg/m 2 or BMI of 27 kg/m 2 and at least one weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia, or obstructive sleep apnoea
CB1 and GLP-1 receptors cross talk provides new therapies for obesity
CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, or any other GLP-1 drugmaker